Search Results - "He, Hengqiu"

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy

    Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy by He, Hengqiu, Yang, Wendi, Huang, Yusheng, Zhang, Xiaoyue, Peng, Yuan, Yang, Zhenzhou

    Published in Angiogenesis (London) (01-02-2022)
    “…Anaplastic lymphoma kinase (ALK)/epidermal growth factor receptor (EGFR) co-alterations in adenocarcinomas are rare and no therapeutic consensus is reached…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma

    ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma by Yang, Wendi, Chen, Kehong, Yu, Qian, Liao, Rongxin, He, Hengqiu, Peng, Yuan, Yang, Zhenzhou, Zhang, Xiaoyue

    Published in Cancer medicine (Malden, MA) (01-07-2023)
    “…Background Lung adenocarcinoma (LUAD) is a common subtype of non‐small cell lung cancer with high morbidity and mortality rates and is usually detected at…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer

    Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer by Liao, Rongxin, Chen, Kehong, Li, Jinjin, He, Hengqiu, Yi, Guangming, Huang, Mingfeng, Chen, Rongrong, Shen, Lu, Zhang, Xiaoyue, Xu, Zaicheng, Yang, Zhenzhou, Peng, Yuan

    Published in Cancer research and treatment (01-07-2023)
    “…Oligometastatic non-small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    THU-455 Efficacy and Safety of Hypofractionated Radiotherapy Combined with Sintilimab and Bevacizumab in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A preliminary single-center prospective study

    THU-455 Efficacy and Safety of Hypofractionated Radiotherapy Combined with Sintilimab and Bevacizumab in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A preliminary single-center prospective study by Fu, Xiao, He, Mingfeng, Yang, Yixuan, Zhang, Dazhi, He, Hengqiu, Jiang, Xuan

    Published in Journal of hepatology (01-06-2024)
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    IL-17A's role in exacerbating radiation-induced lung injury: Autophagy impairment via the PP2A-mTOR pathway

    IL-17A's role in exacerbating radiation-induced lung injury: Autophagy impairment via the PP2A-mTOR pathway by Liu, Liangzhong, Yi, GuangMing, Li, Xiaohong, Chen, Cai, Chen, Kehong, He, Hengqiu, Li, Jinjin, Cai, Fanghao, Peng, Yuan, Yang, Zhenzhou, Zhang, Xiaoyue

    “…Radiation-induced lung injury (RILI) is a serious complication of radiotherapy, and the role of IL-17A in this process is not well understood. While IL-17A has…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy

    Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy by He, Hengqiu, Yang, Wendi, Huang, Yusheng, Zhang, Xiaoyue, Peng, Yuan, Yang, Zhenzhou

    Published in Angiogenesis (01-02-2022)
    Get full text
    Report
    Save to List
    Saved in:

Search Tools: